Anadys Pharmaceuticals Inc. (ANDS)

[Hedge Starz]

biotechs burn cash. it is what they do when they are in r and D and trial phases. were you expecting them to sell food on the side for cash ahhahaha. $1.25 next week.

[Hedge Starz]

ughhh no look at chart. they took it back to 1.09. 3q of 2011 is when the big action hits so i guess it is possible for it to drop for like a month BUT long term it is going north. i had my first long chat with ANDS today about big pharma JV and timelines. this is a good hold. say what you want about what happens the next 4 weeks or so. funds have been buying at 1.4-1.6-2 and feel fine.

[Snizzle]

Wow they only lost 6mill compared to 6.2mil last year same quarter, they sure are turning things around!!NOT I look for this to drop hard and fast shortly!!! IMO

[Hedge Starz]

got me some. they will bounce this back to 1.11 eod

[surf1944]

http://www.briefing.com/GeneralContent/Active/Investor/TickerSearch/QuickSearch.aspx

[surf1944]

http://www.nasdaq.com/asp/holdings.asp?symbol=ANDS&selected=ANDS&FormType=Institutional

[surf1944]

Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights

Press Release Source: Anadys Pharmaceuticals, Inc. On Thursday May 5, 2011, 4:05 pm EDT

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS - News), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the first quarter ended March 31, 2011.

"The ANA598 Phase IIb study currently underway will expand the profile of ANA598 in important ways," said Steve Worland, Ph.D., President and CEO of Anadys. "We expect to increase the ANA598 safety database by approximately 200 patients, with dosing through 24 weeks completed by year-end, and to characterize ANA598's activity in combination with pegylated interferon and ribavirin in treatment-experienced patients. The acquisition of these data should significantly enhance ANA598's readiness for Phase III activities."

Development Program Highlights

ANA598 Phase IIb Study. During the first quarter, Anadys commenced dosing HCV patients in an ongoing Phase IIb study in which ANA598 is being tested in combination with interferon and ribavirin in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin. Approximately 275 patients are expected to be enrolled in the study. The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24. The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011. Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.
ANA773 Phase IIa Study. The Company is preparing to commence during the second quarter a 28-day study of ANA773 in combination with ribavirin, and may test ANA773 as triple therapy in combination with ribavirin and a DAA in subsequent cohorts. Anadys intends to conduct this Phase IIa study of ANA773 in Europe and expects that up to approximately 75 patients will participate in the trial, including approximately 20 patients planned for the first two cohorts with ribavirin. Anadys expects to receive Week 4 viral load data for these first two cohorts in the fourth quarter of 2011.


Financial Results and Highlights

As of March 31, 2011, Anadys' cash, cash equivalents and securities available-for-sale totaled $32.8 million compared to $38.0 million as of December 31, 2010. The decrease in cash, cash equivalents and securities available-for-sale is the result of our cash utilization to fund operations during the first three months of 2011.

Total operating expenses were $6.5 million for the first quarter of 2011, compared to $5.4 million for the first quarter of 2010. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.5 million for the first quarter of 2011 and 2010.

Research and development expenses were $5.0 million for the first quarter of 2011, compared to $3.7 million for the first quarter of 2010. The $1.3 million increase was primarily attributable to a $1.1 million increase in ANA598 development costs and a $0.3 million increase in ANA773 development costs.

General and administrative expenses were relatively consistent at $1.6 million for the first quarter of 2011 and 2010.

The net loss was $6.0 million for the first quarter of 2011, compared to a net loss of $6.2 million for the first quarter of 2010. Included in the net loss for the first quarter of 2011 is a $0.6 million non-cash gain resulting from a decrease in the liability associated with our common stock warrants from December 31, 2010 to March 31, 2011. The warrants were issued in connection with our "registered direct" offering in June 2009. Basic and diluted net loss per common share was $0.10 in the first quarter of 2011, compared to $0.17 in the first quarter of 2010. Non-cash share-based expense resulted in a $0.01 increase in basic and diluted net loss per share for the first quarter of 2011 and 2010.

Conference Call Webcast

Anadys will host a conference call and webcast at 5:00 pm Eastern Daylight Time today to discuss its first quarter 2011 financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 23621944. The webcast and telephone replay will be available through May 19, 2011.

Condensed Consolidated Financial Statements
http://finance.yahoo.com/news/Anadys-Pharmaceuticals-prnews-3038064566.html?x=0&.v=1

[surf1944]

http://www.form4oracle.com/company/anadys-pharmaceuticals-inc-ands/company-transactions?id=7978

[Hedge Starz]

i think we may see a partnership anounced here in next few weeks. about this time

[Hedge Starz]

thoughts on current chart setup???????

[Hedge Starz]

shaping up very nicely now. break and hold 1.20 and it is game over.

[conix]

ANDS chart

[Hedge Starz]

it's gonna breakout tomorrow IMO. close over 20sma imminent, and this one likes to run nicely on that. we may be due for a longer uptrend back to the 1.60 secondary placement price. this biotech industry has been flooded with good news the past few days and there are are some events in early May that may affect us significantly.

[conix]

ANDS

[Hedge Starz]

might get a 20sma break-hold today.

[Hedge Starz]

http://seekingalpha.com/news-article/703140-piper-jaffray-maintains-overweight-on-anadys-pharmaceuticals-ands

[Hedge Starz]

i'm buying here

[Hedge Starz]

pathetic volume today. just pathetic

[surf1944]

2. Anadys Pharmaceuticals Inc. (ANDS):

Biotechnology Industry. Market cap of $76.51M.

Insider Transactions: Insiders purchased an average of 1,967,596 shares per year over the last two years.

Institutional Transactions: Institutional investors currently own 52,496,565 shares vs. 43,182,041 shares held three months ago (21.57% change).

Other Sentiment Data: Short float at 1.64%, which implies a short ratio of 1.35 days. The stock has lost -35.89% over the last year.

Recent Developments: Announced that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients (January 2011). Steven H. Holtzman provided notice of his resignation from the Board of Directors in light of his appointment as Executive Vice President, Corporate Development of Biogen Idec Inc. (January 2011).

http://seekingalpha.com/article/249698-3-biotech-stocks-snapped-up-by-insiders-and-institutional-investors?source=yahoo

[Hedge Starz]

yep. had sma cross but look to play sma bounce here at 1.24 or so after neg macd cross hopefullly.............that would be nice

[gotinearly]

Anadys Pharmaceuticals Augments Management Team and Board of Directors

Anadys (NASDAQ:ANDS)
Intraday Stock Chart
Today : Friday 7 January 2011
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced the following additions and changes to its management team and Board of Directors:

Kevin L. Eastwood has joined Anadys as Senior Vice President, Corporate Development
James Appleman, Ph.D. has been promoted to Senior Vice President, Research and Chief Scientific Officer
James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer, has been appointed to the Company's Board of Directors
Stelios Papadopoulos, Ph.D. has been named Chairman of the Board
"I am delighted with the addition of Kevin Eastwood to our management team and the additional responsibilities for Drs. Appleman, Freddo and Papadopoulos," said Steve Worland, Ph.D., Anadys' President and CEO. "With these changes in place, we are well-positioned to execute our corporate objectives in the coming year."

Mr. Eastwood, who joins Anadys from Ambrx, Inc., will be responsible for the Company's business development and strategic planning activities, reporting to Steve Worland, Ph.D., President and Chief Executive Officer. Mr. Eastwood has held a number of prior business development positions, including the senior corporate development positions at Ambrx, Inc. and Achillion Pharmaceuticals, Inc. In these positions he was responsible for executing business transactions with a number of leading biotechnology and pharmaceutical companies, including Pfizer, Inc., Merck and Co., Inc., Eli Lilly and Company, and Gilead Sciences, Inc. Mr. Eastwood began his pharmaceuticals career in sales and marketing at Marion Laboratories and transitioned to business development while at Agouron Pharmaceuticals, Inc., now a part of Pfizer. He holds a B.S. in Biology from Missouri State University.

Dr. Appleman, who has been with Anadys since 2001 in positions of increasing responsibility, most recently as Senior Vice President, Research, played pivotal roles in the invention and characterization of the Company's drug development candidates ANA598 and ANA773. Dr. Appleman will continue to be responsible for non-clinical aspects of both development programs. Dr. Appleman was a faculty member at St. Jude Children's Research Hospital and subsequently held positions at Gensia, Inc. and Metabasis Therapeutics, Inc. prior to joining Anadys. He received a Ph.D. in Biochemistry from Oklahoma State University and completed his postdoctoral training at Dartmouth Medical School.

Dr. Freddo joined Anadys in 2006 as Chief Medical Officer to build out the Company's clinical and regulatory functions and was named Senior Vice President of Drug Development in 2008. Under his leadership both ANA598 and ANA773 entered clinical development and advanced to their current status. Dr. Freddo joined Anadys from Pfizer, Inc. where he was most recently Vice President, Clinical Site Head and Development Site Head, La Jolla, and led the team responsible for the registration of Sutent®. Prior to Pfizer, Dr. Freddo held a number of drug development positions at Wyeth-Ayerst. Dr. Freddo serves as a member of the Board of Directors for InfuSystems Holdings, Inc. Dr. Freddo received his M.D. and completed his fellowship training at the University of North Carolina and served on the faculty of the UCSD Medical Center prior to joining industry.

Dr. Papadopoulos assumes the role of Chairman of the Board from Steven H. Holtzman, who has resigned from the Board of Directors in association with his recent appointment as Executive Vice President, Corporate Development at Biogen Idec Inc. Dr. Papadopoulos, who is a co-founder of Anadys and has been a member of the Board since 2000, has more than 25 years experience in the biotechnology and pharmaceutical industries as an investment banker, Board member and company founder and investor. Dr. Papadopoulos is a Board member of several companies, including Biogen Idec and Exelixis, Inc., where he is Chairman.

Dr. Papadopoulos added, "On behalf of all of us at Anadys I would like to thank Steve Holtzman for his years of service as a member as well as for serving as Chairman of our Board. We will miss his unique insights and wise counsel, but we wish him well in his new endeavor at Biogen Idec."

[GABRIELXX]

Yup,those insiders transaction just popup on my screener,interesting..

[gotinearly]

They have purchased $8million worth in 2010. They must know something to put up that kind of coin.

[DewDiligence]

QVT financial invested in some of the biggest biotech busts such as MDVN (#msg-47342464) and Point Therapeutics (#msg-12777260).

[DewDiligence]

ANA598 is a useless drug, IMO: #msg-58413513.

[tommer]

this thing used to be hot what happened?

[gotinearly]

look at these inside purchases...WOW

http://www.form4oracle.com/company/anadys-pharmaceuticals-inc-ands/company-transactions?id=7978

[Flobewan]

Kind of late, peeps sleeping

[gotinearly]

Nice chart...

[Flobewan]

I hope it pops

[gotinearly]

Anybody out there? This is about to pop

[gotinearly]

HUGE NEWS!!!!!!!!!!!

[gotinearly]

Yehaw, I was a little early to the party but am solid green now.

[pj McMulligan]

Is anyone adding ANDS today? The chart pinged my pincher scan, technicals look good on this one for bottom reversal imo.

[RainmanOregon]

Hey D...now this was a great call. Kudos to you sir. Liquid as all get out and green...two of my favorite things.

[Tadaaa]

Touched the 34 EMA, Lookin Good !!

[Hedge Starz]

new highs coming here soon. i see 1.20s on the way. not selling. maybg i'm dumb bid really stacking on 1.12s now

[ralfalf]

Looking good here for sure. Great volume today too. I never did pick up anymore shares but have 5K at a buck.

[Hedge Starz]

breaking 20sma @ $1.04 would be nice

[Hedge Starz]

just got some at .912. we have negative macd cross to work with still in next day or so, but i feel this will turn around in less than 30 days.

RSI is ~15

We have SMAs creeping down that will be catalysts on short coverings and any good news.

The Secondary offering was $1.8 ..... a 50% discount

[ralfalf]

I was hoping $1. would hold but the last 3 days we've been below $1. enough to make me think we will drop lower. I don't have many shares here yet.

[Hedge Starz]

think this turns here?

[mlkrborn]

ANDS went further down to 1.02!

[ralfalf]

Pretty quiet here lately but to me it's looking oversold. Hoping to catch a small bounce here.
In today for 5K @ $1.

[sigsmoke]

Let's see where we are at the end of next week after the conference. Chart is telling me to buy here. I think ANDS reverses in the near future. Once this closes over 1.30 buyers will be jumping in bigtime!

[DewDiligence]

and when its on its own it can't go up?

No one said that. My previous post was a reply to your assertion that the stock was “oversold” because of the October financing, and I explained why such an assertion is misguided.

Out.

[sigsmoke]

LOL, and when its on its own it can't go up? If price drops below 1.25 I am out. Not much risk imo.

[sigsmoke]

Exactly! Technically this should go no lower than 1.25. Looking pretty good today in a crappy market. Bargain compared to price of recent stock offering. Conference presentation next week. If if breaks down below 1.25, sell. Chart says otherwise. Reward greatly outweighs the risk imo.

[DewDiligence]

The reason ANDS is oversold is due to the recent stock offering.

Your reasoning is backwards. During the 30-day period following an underwritten financing, the underwriter typically supports the share price; this is one of the reasons firms opt to use an underwriter rather than selling shares in a direct placement.

The 30-day window following ANDS’ October financing is nearly done; when it is, the share price will be on its own without any help from Lazard.

[xray44b9]

I'm looking at risk/reward here. IMO this is way-skewed in favor of reward (at this price point) regardless of what you think their prospects are for success in the marketplace. Hell, there's a variety of opinions on that.